ORAGENICS, INC. Impairment of Long-Lived Assets Held-for-use
ORAGENICS, INC. (OGEN) reported Impairment of Long-Lived Assets Held-for-use of $0 for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2019-03-29
- ORAGENICS, INC. impairment of long-lived assets held-for-use for fiscal 2018 was $0.00.
- ORAGENICS, INC. impairment of long-lived assets held-for-use for fiscal 2017 was $0.00.
- ORAGENICS, INC. impairment of long-lived assets held-for-use for fiscal 2016 was $0.00.
- ORAGENICS, INC. impairment of long-lived assets held-for-use for fiscal 2015 was $0.00.
| Period end | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|
| 2018-12-31 | $0.00 10-K · filed 2019-03-29 |
| 2017-12-31 | $0.00 10-K · filed 2019-03-29 |
| 2016-12-31 | $0.00 10-K · filed 2018-02-16 |
| 2015-12-31 | $0.00 10-K · filed 2017-02-27 |
| 2014-12-31 | $0.00 10-K · filed 2016-03-30 |
| 2013-12-31 | $0.00 10-K · filed 2015-02-27 |
| 2012-12-31 | $0.00 10-K · filed 2014-02-28 |
| 2011-12-31 | $0.00 10-K · filed 2013-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |